The acute effects of dexfenfluramine on human and porcine pulmonary vascular tone and resistance

Chest

Volumn 116, Issue 4, 1999, Pages 921-930

  Higenbottam, Timothy ^a,c   Marriott, Helen ^a   Cremona, George ^b   Laude, Elizabeth ^a   Bee, Denise ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b IRCCS   (Italy)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Dexfenfluramine; Human; Isolated perfused lung; Porcine; Pulmonary hypertension; Serotonin

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; DEXFENFLURAMINE; INDOMETACIN; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DOSE RESPONSE; HEART LUNG TRANSPLANTATION; HUMAN; HUMAN TISSUE; ISOLATED LUNG; LUNG PERFUSION; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0032716104     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.4.921     Document Type: Article

References (61)

1. 1 Harris P, Heath D. The human pulmonary circulation: its form and function in health and disease. 3rd ed. New York, NY: Churchill Livingstone, 1988
2. 2 Gurtner HP, Gerstsch M, Salzmann C, et al. Haufen sich die primer vaseularen forman des chronischen cor pulmonale? Schweiz Med Wochenschr 1968; 98:1579-1589
3. 3 Douglas JG, Munro JF, Kitchin AF, et al. Pulmonary hypertension and fenfluramine. BMJ 1981; 283:881-883
4. 4 Nall KC, Rubin LJ, Lipkind S, et al. Reversible pulmonary hypertension associated with anorexigen use. Am J Med 1991; 91:97-99
5. 5 Gurtner HP. Aminorex and pulmonary hypertension. Cor Vasa 1985; 27:160-171
6. 6 Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension und fenfluramine use. Br Heart J 1993; 70:537-541
7. 7 Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335:609-616
8. 8 Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2:1142-1145
9. 9 Shinton R, Sagar G, Beevers G. Body fat and stroke: unmasking the hazards of overweight and obesity. J Epidemiol Community Health 1995; 49:259-264
10. 10 Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentamine. N Engl J Med 1997; 337:581-588
11. 11 Leibowitz SF, Weiss GF, Shor-Posner G. Hypothalamic serotonin: pharmacological biochemical and behavioral analyses of its-suppressive actions. Clin Neuropharmacol 1988; 11(suppl I):S51-S71
12. 12 Young R. Aminorex produces stimulus effects similar to amphetamine and unlike those of fenfluramine. Pharmacol Biochem Behav 1992; 42:175-178
13. 3H-Imipramine binding in rat brain membrane: relation to serotonin uptake sites. Life Sci 1988; 42:575-583
14. 14 Buscko N. Effects of fenfluramine on 5-HT uptake and release of rat blood platelets. J Pharmacol 1975; 53:563-568
15. 15 Geller E, Ritvo ER, Freeman BJ, et al. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 1982; 307:165-169
16. 16 Rojansky N, Halbreich U, Zander K, et al. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991; 31:146-152
17. 17 Parsons AA. 5-HT receptors in human and animal cerebrovasculature. Trends Pharmacol Sci 1991; 12:310-315
18. 18 Curson G. Serotonin and appetite. Ann NY Acad Sci 1990; 600:521-531
19. 1 receptors. Psychopharmacology 1989; 97:213-218
20. 20 Mennini T, Bizzi A, Caccia S. Comparative studies on the anorectic activity of d-fenfluramine in mice, rats and guinea pigs. Naunyn-Schmiedeberg's Arch Pharmacol 1991; 343: 483-490
21. 21 Chu A, Cobb FR. Vasoactive effects of serotonin on the proximal coronary arteries in awake dogs. Circ Res 1987; 61(suppl II):81-87
22. 1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of endothelium and tone. Pulm Pharmacol 1994; 7:65-72
23. 1 like receptor-mediated vasoconstriction in human pulmonary artery. Br J Pharmacol 1996; 119:277-282
24. 24 Andersson B, Zimmermann ME, Hedner T, et al. Hemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women. Eur J Clin Pharmacol 1991; 40:249-254
25. 25 Daqing Z, Xiadling N, Zhijun M, et al. Effect of fenfluramine on amelioration of carbohydrate metabolism and correction of prostacyclin/thromboxane imbalance in NIDDM. J Shanghai Second Med Univ 1988; 2:67-73
26. 26 Weir K, Reeve HI, Huang JMC, et al. Anorectic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996; 94:2216-2220
27. 27 Wang JA, Juhaszova M, Conte JV, et al. Action of fenfluramine on voltage gated K+ channels in human pulmonary artery smooth muscle cells. Lancet 1998; 352:290
28. 28 Bradley JD, Zanaboni PB, Dahms TE. Species differences in pulmonary vasoactive responses to histamine, 5-hydroxytryptamine and KCl. J Appl Physiol 1993; 74:139-146
29. 29 Hakim M, Higenbottam TW, Bethune D, et al. Selection and procurement of combined heart and lung grafts for transplantation. J Thorac Cardiovasc Surg 1988; 98:474-479
30. 30 Dinh Xuan AT, Higenbottam TW, Clelland C, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324:1539-1547
31. 31 Dinh Xuan AT, Pepke-Zaba J, Butt AY, et al. Impairment of pulmonary-artery endothelium-dependent relaxation in chronic obstructive lung disease is not due to dysfunction of the endothelial cell membrane receptors nor to L-arginine deficiency. Br J Pharmacol 1993; 109:587-591
32. 32 West JB, Dollery CT. Distribution of blood flow and the pressure relations of the whole lung. J Appl Physiol 1965; 20:175-183
33. 33 Cremona G, Higenbottam T, Takao M, et al. Nature and site of action of endogenous nitric oxide in the vasculature of isolated pig lungs. J Appl Physiol 1997; 82:23-31
34. 34 Glusa E, Richter. Endothelium-dependent relaxation of porcine pulmonary arteries via 5-HT1C like receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 347:471-477
35. 35 Ellis ES, Byrne C, Murphy OE, et al. Mediation by 5-HT2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 1995; 114:400-404
36. 36 Caccia S, Conforti I, Duchier J, et al. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given d- and dl-fenfluramine for 15 days. Eur J Clin Pharmacol 1985; 29:221-224
37. 37 Cremona G, Wood AM, Hall LW, et al. Effect of inhibitors of nitric oxide release and action on the vascular tone in isolated lungs of pig, sheep, dog, man. J Physiol 1994; 48:185-195
38. 38 Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114:464-469
39. 39 Christman BW, McPherson CD, Newman JH. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75
40. 40 Hakim TS, Kelly S. Occlusion pressures vs. micropipette pressures in the pulmonary circulation. J Appl Physiol 1989; 67:1277-1285
41. 41 McMahon TJ, Hood JS, Nossaman BD, et al. Analysis of responses to serotonin in the pulmonary vascular bed of the cat. J Appl Physiol 1993; 75:93-102
42. 42 Boe J, Simonson BG, Stahl E. Effect of histamine, 5-hydroxytryptamine and prostaglandins on isolated human pulmonary arteries. Eur J Respir Dis 1980; 61:12-19
43. 43 Stahl SM, Levin B, Freedman DX. Serotonin depletion by fenfluramine in the carcinoid syndrome. N Engl J Med 1982; 306:429
44. 44 Menys VC, Smith CCT, Lewins P, et al. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci 1996; 91:87-92
45. 3H]5-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes. Eur J Pharmacol 1993; 238:9-17
46. 46 Marsden CA, Tyrer P, Casey P, et al. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxitine, a selective 5-HT uptake inhibitor. J Psychopharmacol 1987; 1:244-250
47. 47 Celada P, Dolera M, Alvarez E, et al. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 1992; 25:243-250
48. 48 Wagner A, Montero D, Martensson B, et al. Effects of fluoxetine treatment of platelet 3H-imipamine binding 5-HT uptake and 5-HT content in major depressive disorder. J Affect Disord 1990; 20:101-113
49. 49 U.S. Department of Health and Human Services Interim Public Health Recommendations: cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: Morbid Mortal Wkly Rep 1997; 46:1061-1066
50. 50 Hauck AJ, Edwards WD, Danielson GK, et al. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Arch Pathol Lab Med 1990; 114:62-64
51. 51 Robiolio VH. Rigolin JS, Wilson JK, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92:790-795
52. 52 Pellikka AJ. Tabik BK, Khandheria JB, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188-1196
53. 53 Himelman NB, Schiller NB. Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease. Am J Cardiol 1989; 63:347-352
54. 54 Hart CM, Block ER. Lung serotonin metabolism. Clin Chest Med 1989; 10:59-70
55. 55 Holmsen H, Weiss HJ. Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol 1970; 19:643-649
56. 56 Herve P, Drouet L, Dosquet C, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1990; 88:117-120
57. 57 Sato K, Webb S, Tucker A, et al. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1992; 145:793-797
58. 58 Tschopp TB, Zucker MB. Hereditary defect in platelet in rats. Blood 1972; 40:217-226
59. 59 Kentara D, Susic D, Veljkovic V, et al. Pulmonary artery pressure in rats with hereditary platelet function defect. Respiration 1988; 54:110-114
60. 60 Celada P, Martin F, Artigas, F. Effect of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 1994; 55:1237-1243
61. 61 Redmon B, Raatz S, Bantle JP. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:1773-1774